Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Senior Editor, Pharma Insights
+41 year(s) experience
Scrip
By Sten Stovall 05 Sep 2017
Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.
Topic Business strategies
Scrip
By Sten Stovall 01 Sep 2017
Ireland-based Jazz Pharma is extending its shift away from specialty pharma with an option-based deal with ImmunoGen involving three antibody-drug conjugate programs.
Topic Business strategies
Scrip
By Sten Stovall 23 Aug 2017
UK-based Destiny Pharma hopes its planned IPO will attract investor demand.
Topic Clinical trials
Scrip
By Sten Stovall 18 Jul 2017
Datamonitor Healthcare's latest sector analysis indicates that the pharma industry's 10 biggest companies.
Scrip
By Sten Stovall 26 Jun 2017
Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis.
Scrip
By Sten Stovall 19 Jun 2017
Roche CEO Severin Schwan says analysts at ASCO missed a key APHINITY message on Herceptin follow-on Perjeta.
Topic Research
Pink Sheet
By Sten Stovall 05 Apr 2017
Neurotrope's novel bryostatin treatment for Alzheimer's, AstraZeneca's durvalumab in bladder cancer, and Actelion’s antibiotic cadazolid are among a raft of therapies scheduled for major data read-outs or approval decisions in Q2 2017. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at some crucial drug displays likely over the next three months.
Topic Alzheimers Cancer Clinical trials
Pink Sheet
By Sten Stovall 05 Apr 2017
Biogen's chief medical officer says iPhone technology should in future be used for early warning diagnosis of Alzheimer's Disease.
Topic Alzheimers
Pink Sheet
By Sten Stovall 15 Mar 2017
Discussion with regulators on conditional regulatory pathways will now begin after strong and durable immune responses against the Zaire Ebola virus were reported in a UK-based Phase I trial in healthy volunteers usingthefiloviruses vaccine Ad26.ZEBOV developed by Bavarian Nordic AS and licensed by Johnson & Johnson'sJanssen Pharmaceutical Cos.
Topic Rare Disease Research
Scrip
19 Sep 2017
Scrip
15 Sep 2017
Scrip
13 Sep 2017
Scrip
08 Sep 2017
Scrip
08 Sep 2017
Scrip
08 Sep 2017
Scrip
08 Sep 2017
Scrip
08 Sep 2017
Scrip
06 Sep 2017
Scrip
04 Sep 2017
Scrip
04 Sep 2017
Scrip
02 Sep 2017
Scrip
31 Aug 2017
Scrip
31 Aug 2017
Scrip
31 Aug 2017
